{
  "report_rows": [
    {
      "kpi": "Adj. Diluted EPS (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$2.12 vs. cons $2.08 (+1.9%)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Organic Sales Growth (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~5.1% vs. cons 4.77% (+33bp)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Organic OI Margin (Q2 2026)",
      "prediction": "IN-LINE",
      "answer": "pred ~18.7% vs. cons 18.67% (+3bp)",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 Adj. EPS (FY2026)",
      "prediction": "UNCHANGED",
      "answer": "guide $8.03-$8.23 reaffirmed vs. cons $8.19",
      "confidence": "HIGH"
    },
    {
      "kpi": "Q3 2026 Adj. EPS (Q3 2026)",
      "prediction": "BETTER",
      "answer": "guide ~$2.15 vs. cons $2.08 (+3.4%)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "H2 Organic Sales Growth (H2 2026)",
      "prediction": "BETTER",
      "answer": "guide 6-7% reaffirmed vs. cons ~4.8% Q3",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 2.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 4.5,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "FOLLOW-THROUGH \u2014 sell-side revises Q3/FY estimates up on Q3 guide above consensus; consistent with all 3 prior Archetype A quarters",
  "day5_confidence": "MEDIUM"
}